Literature DB >> 8887491

In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector.

P G Speck1, S Efstathiou, A C Minson.   

Abstract

The utilization of herpes simplex virus (HSV) as a vector for gene delivery to the nervous system or as a live vaccine delivery system is dependent on the construction and characterization of disabled virus mutants which are unable to cause disease. Under certain circumstances, however, replication-defective vectors may carry a potential risk if they can be efficiently complemented by a co-infecting wild-type virus. Stocks of defective vectors should, therefore, be free from replication-competent virus, and helper cell lines should be incapable of generating replication-competent virus by recombination between the vector and the complementary gene. We describe a glycoprotein H-negative (gH-) virus/helper cell line combination which generates helper-free defective virus stocks containing replication-competent virus at a frequency no higher than 1 in 10(9) p.f.u. This virus/helper cell system provides a suitable background for the construction of safe replication-defective gene delivery vectors. In vivo studies demonstrate that gH- virus is unable to initiate disease in mice and establishes latency at low efficiency compared to wild-type HSV. To determine whether gH- virus can be complemented by wild-type virus in vivo, mice were infected with a variety of mixtures of these viruses. Complementation was observed in a minority of animals infected with more than 10(6) p.f.u. of both wild-type and defective virus but the most common observation was that the presence of defective virus suppressed entry of wild-type virus into the nervous system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887491     DOI: 10.1099/0022-1317-77-10-2563

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 4.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

5.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Coinfection in the host can result in functional complementation between live vaccines and virulent virus.

Authors:  Huai Xu; Andrea L Krieter; Nagendraprabhu Ponnuraj; Yvette Yung-Tien Tien; Taejoong Kim; Keith W Jarosinski
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

7.  Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Authors:  Christopher Petro; Pablo A González; Natalia Cheshenko; Thomas Jandl; Nazanin Khajoueinejad; Angèle Bénard; Mayami Sengupta; Betsy C Herold; William R Jacobs
Journal:  Elife       Date:  2015-03-10       Impact factor: 8.140

8.  A codon-shuffling method to prevent reversion during production of replication-defective herpesvirus stocks: Implications for herpesvirus vaccines.

Authors:  Gang Li; Charles Ward; Rukhsana Yeasmin; Steven Skiena; Laurie T Krug; J Craig Forrest
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

Review 9.  Herpes simplex virus interference with immunity: Focus on dendritic cells.

Authors:  Farías Ma; Duarte Lf; Tognarelli Ei; González Pa
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.